Open AccessUtilization of anti–factor Xa levels to guide reversal of oral factor Xa inhibitors in the emergency department
Author(s) -
Anne Zepeski,
Brett Faine,
Anna E. Merrill,
Grerk Sutamtewagul,
Sharathkumar Bhagavathi
Publication year - 2021
Publication title -
american journal of health-system pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.487
H-Index - 96
eISSN - 1535-2900
pISSN - 1079-2082
DOI - 10.1093/ajhp/zxab326
Subject(s) - rivaroxaban , medicine , apixaban , interquartile range , emergency department , prothrombin complex , prothrombin complex concentrate , warfarin , emergency medicine , anesthesia , atrial fibrillation , coagulation , psychiatry
Oral factor Xa inhibitors (FXaIs) are increasingly utilized for outpatient anticoagulation therapy; however, laboratory monitoring is not routinely used to assess the safety and efficacy of these agents. We aimed to evaluate the role of chromogenic anti-factor Xa (anti-Xa) assays in the emergency department (ED) in the setting of patients with an acute bleed or requiring emergent procedures.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom